JDP2 Overexpression Provokes Cardiac Dysfunction in Mice

Overview

Journal Sci Rep

Specialty Science

Date 2018 May 18

PMID 29769710

Citations 9

Authors

Jacqueline Heger

Julia Bornbaum

Alona Wurfel

Christian Hill

Nils Brockmann

Renata Gaspar

Janos Paloczi

Zoltan V Varga

Marta Sarkozy

Peter Bencsik

Tamas Csont

Szilvia Torok

Baktybek Kojonazarov

Ralph Theo Schermuly

Kerstin Bongler

Mariana Parahuleva

Peter Ferdinandy

Rainer Schulz

Gerhild Euler

Affiliations

Soon will be listed here.

Abstract

The transcriptional regulator JDP2 (Jun dimerization protein 2) has been identified as a prognostic marker for patients to develop heart failure after myocardial infarction. We now performed in vivo studies on JDP2-overexpressing mice, to clarify the impact of JDP2 on heart failure progression. Therefore, during birth up to the age of 4 weeks cardiac-specific JDP2 overexpression was prevented by doxycycline feeding in transgenic mice. Then, JDP2 overexpression was started. Already after 1 week, cardiac function, determined by echocardiography, decreased which was also resembled on the cardiomyocyte level. After 5 weeks blood pressure declined, ejection fraction and cardiac output was reduced and left ventricular dilatation developed. Heart weight/body weight, and mRNA expression of ANP, inflammatory marker genes, collagen and fibronectin increased. Collagen 1 protein expression increased, and fibrosis developed. As an additional sign of elevated extracellular matrix remodeling, matrix metalloproteinase 2 activity increased in JDP2 mice. Thus, JDP2 overexpression is deleterious to heart function in vivo. It can be concluded that JDP2 overexpression provokes cardiac dysfunction in adult mice that is accompanied by hypertrophy and fibrosis. Thus, induction of JDP2 is a maladaptive response contributing to heart failure development.

Citing Articles

Identification and characterization of novel ferroptosis-related genes in acute myocardial infarction.

Zhou Q, Shi R, Liu J, Liu Z Hum Genomics. 2024; 18(1):123.

PMID: 39538299 PMC: 11562590. DOI: 10.1186/s40246-024-00693-7.

Bioinformatics-based Analysis and Verification of Chromatin Regulators and the Mechanism of Immune Infiltration Associated with Myocardial Infarction.

Zhao H, Tang N, Xu L, Li J, Pi J, Chu Q Curr Med Chem. 2024; 32(1):188-209.

PMID: 39354722 DOI: 10.2174/0109298673265089231117054348.

Single-cell analysis of chromatin and expression reveals age- and sex-associated alterations in the human heart.

Read D, Booth G, Daza R, Jackson D, Gladden R, Srivatsan S Commun Biol. 2024; 7(1):1052.

PMID: 39187646 PMC: 11347658. DOI: 10.1038/s42003-024-06582-y.

Jun Dimerization Protein 2 (JDP2) Increases p53 Transactivation by Decreasing MDM2.

Price K, Yang W, Cardoso L, Wang C, Yang R, Yang W Cancers (Basel). 2024; 16(5).

PMID: 38473360 PMC: 10930919. DOI: 10.3390/cancers16051000.

Transcription factor JDP2 activates PDE4B to participate in hypoxia/reoxygenation-induced H9c2 cell injury.

Li S, Chen Y, Jia Y, Xue T, Hou X, Zhao Z Exp Ther Med. 2022; 23(5):340.

PMID: 35401806 PMC: 8988156. DOI: 10.3892/etm.2022.11270.

References

Maciejak A, Kiliszek M, Michalak M, Tulacz D, Opolski G, Matlak K . Gene expression profiling reveals potential prognostic biomarkers associated with the progression of heart failure. Genome Med. 2015; 7(1):26. PMC: 4432772. DOI: 10.1186/s13073-015-0149-z. View

Maruyama K, Fukasaka M, Vandenbon A, Saitoh T, Kawasaki T, Kondo T . The transcription factor Jdp2 controls bone homeostasis and antibacterial immunity by regulating osteoclast and neutrophil differentiation. Immunity. 2012; 37(6):1024-36. DOI: 10.1016/j.immuni.2012.08.022. View

Klinkhammer B, Floege J, Boor P . PDGF in organ fibrosis. Mol Aspects Med. 2017; 62:44-62. DOI: 10.1016/j.mam.2017.11.008. View

Aronheim A, Zandi E, Hennemann H, Elledge S, Karin M . Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions. Mol Cell Biol. 1997; 17(6):3094-102. PMC: 232162. DOI: 10.1128/MCB.17.6.3094. View

Kalfon R, Haas T, Shofti R, Moskovitz J, Schwartz O, Suss-Toby E . c-Jun dimerization protein 2 (JDP2) deficiency promotes cardiac hypertrophy and dysfunction in response to pressure overload. Int J Cardiol. 2017; 249:357-363. DOI: 10.1016/j.ijcard.2017.08.074. View

Langer M, Luttecke D, Schluter K . Mechanism of the positive contractile effect of nitric oxide on rat ventricular cardiomyocytes with positive force/frequency relationship. Pflugers Arch. 2003; 447(3):289-97. DOI: 10.1007/s00424-003-1187-8. View

Katz S, Aronheim A . Differential targeting of the stress mitogen-activated protein kinases to the c-Jun dimerization protein 2. Biochem J. 2002; 368(Pt 3):939-45. PMC: 1223036. DOI: 10.1042/BJ20021127. View

Jin C, Ugai H, Song J, Murata T, Nili F, Sun K . Identification of mouse Jun dimerization protein 2 as a novel repressor of ATF-2. FEBS Lett. 2001; 489(1):34-41. DOI: 10.1016/s0014-5793(00)02387-5. View

Kupai K, Szucs G, Cseh S, Hajdu I, Csonka C, Csont T . Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 2010; 61(2):205-9. DOI: 10.1016/j.vascn.2010.02.011. View

10.

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

11.

Katz S, Heinrich R, Aronheim A . The AP-1 repressor, JDP2, is a bona fide substrate for the c-Jun N-terminal kinase. FEBS Lett. 2001; 506(3):196-200. DOI: 10.1016/s0014-5793(01)02907-6. View

12.

Kocsis G, Sarkozy M, Bencsik P, Pipicz M, Varga Z, Paloczi J . Preconditioning protects the heart in a prolonged uremic condition. Am J Physiol Heart Circ Physiol. 2012; 303(10):H1229-36. DOI: 10.1152/ajpheart.00379.2012. View

13.

Darlyuk-Saadon I, Weidenfeld-Baranboim K, Yokoyama K, Hai T, Aronheim A . The bZIP repressor proteins, c-Jun dimerization protein 2 and activating transcription factor 3, recruit multiple HDAC members to the ATF3 promoter. Biochim Biophys Acta. 2012; 1819(11-12):1142-53. PMC: 3551276. DOI: 10.1016/j.bbagrm.2012.09.005. View

14.

Jin C, Kato K, Chimura T, Yamasaki T, Nakade K, Murata T . Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2. Nat Struct Mol Biol. 2006; 13(4):331-8. DOI: 10.1038/nsmb1063. View

15.

Bui A, Horwich T, Fonarow G . Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2010; 8(1):30-41. PMC: 3033496. DOI: 10.1038/nrcardio.2010.165. View

16.

Liu J, Rigel D . Echocardiographic examination in rats and mice. Methods Mol Biol. 2009; 573:139-55. DOI: 10.1007/978-1-60761-247-6_8. View

17.

Kehat I, Heinrich R, Ben-Izhak O, Miyazaki H, Gutkind J, Aronheim A . Inhibition of basic leucine zipper transcription is a major mediator of atrial dilatation. Cardiovasc Res. 2006; 70(3):543-54. DOI: 10.1016/j.cardiores.2006.02.018. View

18.

Nian M, Lee P, Khaper N, Liu P . Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004; 94(12):1543-53. DOI: 10.1161/01.RES.0000130526.20854.fa. View

19.

Koren L, Elhanani O, Kehat I, Hai T, Aronheim A . Adult cardiac expression of the activating transcription factor 3, ATF3, promotes ventricular hypertrophy. PLoS One. 2013; 8(7):e68396. PMC: 3707568. DOI: 10.1371/journal.pone.0068396. View

20.

Hill C, Wurfel A, Heger J, Meyering B, Schluter K, Weber M . Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. Cardiovasc Res. 2013; 99(1):121-8. DOI: 10.1093/cvr/cvt094. View